USA – Hologic, a leader in women’s health technology, has announced a significant acquisition agreement to purchase Gynesonics, a privately held medical device company, for approximately US $350 million.
The deal, which includes working capital and other customary adjustments, is expected to close pending regulatory approval.
This acquisition highlights Hologic’s ongoing commitment to expanding its offerings in the field of minimally invasive surgery, specifically targeting treatments for uterine fibroids, which affect millions of women worldwide.
Gynesonics, based in Redwood City, California, is best known for developing the Sonata System, an innovative medical technology designed for the diagnostic imaging and treatment of symptomatic uterine fibroids.
The system offers a minimally invasive, incision-free solution for women suffering from fibroid-related symptoms such as heavy menstrual bleeding.
The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation, allowing physicians to precisely target fibroids without surgery.
This revolutionary system is already FDA-cleared, marking it as a safe and effective option for treating uterine fibroids.
“Gynesonics’ Sonata System complements our offering and will give GYN surgeons across the globe an expanded range of options to treat women suffering from heavy periods and fibroids,” said Brandon Schnittker, Division President of Surgical Solutions at Hologic.
“This acquisition furthers our commitment to providing women with minimally invasive treatment options. We are enthusiastic about the future as we work to expand access to and drive innovation for treatments that enhance women’s quality of life.”
A strategic move for growth and innovation
Hologic, headquartered in Marlborough, Massachusetts, has a strong portfolio in women’s health and has been actively expanding its offerings through strategic acquisitions.
The purchase of Gynesonics is part of a broader strategy to incorporate new, minimally invasive technologies that provide better patient outcomes and fewer risks compared to traditional surgery.
In recent years, Hologic has made several significant acquisitions to enhance its capabilities in women’s health, including Endomagnetics, Biotheranostics, Somatex, and Acessa Health.
With each acquisition, the company has bolstered its portfolio in areas such as breast cancer surgery, molecular diagnostics, and fibroid treatment.
The Sonata System, which has treated over 10,000 women globally, is seen as a major addition to Hologic’s surgical solutions lineup, complementing the Acessa ProVu system acquired in 2020, which also targets uterine fibroids.
Driving future innovation and expanding access
In addition to its proven clinical benefits, the Sonata System recently underwent a technology upgrade with the launch of SMART OS 2.4 software in September 2024.
This new software enhances the system’s diagnostic and treatment capabilities, reflecting Gynesonics’ commitment to ongoing innovation.
Hologic plans to leverage its global infrastructure to expand access to this cutting-edge technology.
According to industry analysts, Gynesonics fits well within Hologic’s strategy of acquiring early-stage technologies that can benefit from the company’s resources and scale.
“The company has been focused on targets that have products early in their growth trajectory and could benefit from Hologic’s infrastructure and come at a price that still allows for other tuck-in acquisitions or share buybacks,” noted analysts from William Blair. “Gynesonics appears to fit the bill here.”
